Filspari (sparsentan) — Highmark
primary immunoglobulin A nephropathy (IgAN) confirmed by biopsy in adults at risk for rapid disease progression (proteinuria ≥ 0.5 g/day)
Initial criteria
- age ≥ 18 years
- diagnosis of primary IgAN confirmed by biopsy
- at risk for rapid disease progression evidenced by proteinuria ≥ 0.5 g/day
- experienced therapeutic failure, contraindication, or intolerance to a maximally tolerated dose of one of the following: ACE inhibitor OR ARB
- will not use Filspari in combination with a renin-angiotensin system inhibitor (ACE inhibitor, ARB, aliskiren) OR any endothelin receptor antagonist (e.g., Letairis, Opsumit, Tracleer)
Reauthorization criteria
- experienced a reduction in proteinuria from baseline
- will not use in combination with a renin-angiotensin system inhibitor (ACE inhibitor, ARB, aliskiren) OR any endothelin receptor antagonist (e.g., Letairis, Opsumit, Tracleer)
Approval duration
12 months